Payward Seeks First CFTC-Regulated Deployer Status on Hyperliquid
Payward, parent company of Kraken, is pursuing approval to become the first CFTC-regulated deployer of HIP-3 markets on Hyperliquid, allowing it to offer on-chain perpetual futures to US clients through its subsidiary Bitnomial. The move requires regulatory sign-off and could reshape how US derivatives trading integrates blockchain infrastructure.
Written by CoinArticle’s AI Newsroom · from 2 cited sources. How we work
The Proposal
Payward disclosed plans on October 26 to deploy HIP-3 markets on Hyperliquid through Bitnomial, its CFTC-regulated derivatives subsidiary. HIP-3 refers to Hyperliquid's framework for permissioned market deployers—entities authorized to operate on-chain perpetual futures venues on the protocol. If approved, Payward would be the first US-regulated entity to hold this role, according to Hyperliquid's announcement.
Regulatory Path and Implications
The plan remains subject to CFTC approval, which Payward must obtain before Bitnomial can formally launch HIP-3 markets. Hyperliquid framed the bid as a test case for integrating regulated derivatives venues with blockchain infrastructure. If granted, it would allow Payward to offer on-chain perpetual futures to US clients within a CFTC-compliant wrapper, potentially establishing a template for how other regulated derivatives platforms could deploy to decentralized protocols.
Why It Matters
For Traders
Approval would give US-based traders regulated on-chain access to Hyperliquid perpetuals; the timeline and exact product details remain pending CFTC decision.
For Investors
A CFTC-regulated HIP-3 deployer sets precedent for how centralized compliance integrates with decentralized trading infrastructure, potentially opening new capital sources to Hyperliquid.
For Builders
The HIP-3 framework would have its first major test under US regulatory oversight, signaling how protocols can support permissioned deployments without sacrificing composability.
This article is for information only and is not financial advice. Read the full disclaimer.
